Partnership to Fight Chronic Disease Statement on Americans’ Access to Anti-Obesity Medications
- Apr 3, 2025
- 1 min read
April 4, 2025 (Washington, D.C.) – The Partnership to Fight Chronic Disease (PFCD) released the following statement in response to the announcement of the Contract Year (CY) 2026 MA and Part D final rule that will not include coverage of anti-obesity medications (AOMs).
“There are many factors that contribute to America’s obesity epidemic. There are also many pathways to address it. Today’s decision blocks a major avenue for millions of Medicare and Medicaid patients who, without plan coverage, will not be able to access anti-obesity medications.
“Patients and doctors deserve to have the latest scientific innovation on the table when making medical decisions. We are hopeful that, given the Trump administration’s mission to combat chronic disease, an alternative path will soon emerge, one that expands access to this important class of medications and eases obesity’s economic toll on our health care system.”
For more information, please visit www.fightchronicdisease.org/obesity.
###